Gualtiero Alvisi

Prof. Gualtiero Alvisi

University of Padova
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2012 in Nature
Verified
Journal Article
Closed access
PDF file
APAndreas Pichlmair
Andreas Pichlmair
KKKumaran Kandasamy
Kumaran Kandasamy
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
OMOrla Mulhern
Orla Mulhern
RSRoberto Sacco
Roberto Sacco
GSGiulio Superti-Furga
Giulio Superti-Furga

1 July 2012 in Cell Host & Microbe
Verified
Journal Article
Closed access
ARAlessia Ruggieri
Alessia Ruggieri
EDEva Dazert
Eva Dazert
PMPhilippe Metz
Philippe Metz
SHSarah Hofmann
Sarah Hofmann
JBJan-Philip Bergeest
Jan-Philip Bergeest
RBRalf Bartenschlager
Ralf Bartenschlager

1 March 2011 in RNA Biology
Verified
Journal Article
Closed access
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
VMVanesa Madan
Vanesa Madan
RBRalf Bartenschlager
Ralf Bartenschlager
Hepatitis C virus (HCV) is a major human pathogen, persistently infecting more than 170 million individuals worldwide. The recent establishment of fully permissive culture systems allowed unravelin...

1 August 2015 in Journal of Virology
Verified
Journal Article
Open access
PDF file
PMPhilippe Metz
Philippe Metz
ACAbhilash Chiramel
Abhilash Chiramel
LCLaurent Chatel-Chaix
Laurent Chatel-Chaix
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
PBPeter Bankhead
Peter Bankhead
RBRalf Bartenschlager
Ralf Bartenschlager
Autophagic flux involves formation of autophagosomes and their degradation by lysosomes. Autophagy can either promote or restrict viral replication. In the case of Dengue virus (DENV), several studies report that autophagy supports the viral replication cycle, and describe an increase of autophagic vesicles (AVs) following infection. However, it is unknown how autophagic flux is altered to result in increased AVs. To address this question and gain insight into the role of autophagy during DENV infection, we established an unbiased, image-based flow cytometry approach to quantify autophagic flux under normal growth conditions and in response to activation by nutrient deprivation or the mTOR inhibitor Torin1. We found that DENV induced an initial activation of autophagic flux, followed by inhibition of general and specific autophagy. Early after infection, basal and activated autophagic flux was enhanced. However, during established replication, basal and Torin1-activated autophagic flux was blocked, while autophagic flux activated by nutrient deprivation was reduced, indicating a block to AV formation and reduced AV degradation capacity. During late infection AV levels increased as a result of inefficient fusion of autophagosomes with lysosomes. In addition, endolysosomal trafficking was suppressed, while lysosomal activities were increased. We further determined that DENV infection progressively reduced levels of the autophagy receptor SQSTM1/p62 via proteasomal degradation. Importantly, stable overexpression of p62 significantly suppressed DENV replication, suggesting a novel role for p62 as a viral restriction factor. Overall, our findings indicate that in the course of DENV infection, autophagy shifts from a supporting to an antiviral role, which is countered by DENV. IMPORTANCE Autophagic flux is a dynamic process starting with the formation of autophagosomes and ending with their degradation after fusion with lysosomes. Autophagy impacts the replication cycle of many viruses. However, thus far the dynamics of autophagy in case of Dengue virus (DENV) infections has not been systematically quantified. Therefore, we used high-content, imaging-based flow cytometry to quantify autophagic flux and endolysosomal trafficking in response to DENV infection. We report that DENV induced an initial activation of autophagic flux, followed by inhibition of general and specific autophagy. Further, lysosomal activity was increased, but endolysosomal trafficking was suppressed confirming the block of autophagic flux. Importantly, we provide evidence that p62, an autophagy receptor, restrict DENV replication and was specifically depleted in DENV-infected cells via increased proteasomal degradation. These results suggest that during DENV infection autophagy shifts from a proviral to an antiviral cellular process, which is counteracted by the virus.

1 February 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
ACAntonio Curtoni
Antonio Curtoni
RFRossella Fonnesu
Rossella Fonnesu
APAurora Piazza
Aurora Piazza
SCSignoretto Caterina
Signoretto Caterina
Paolo GaibaniPaolo Gaibani
Paolo Gaibani
Carbapenemase-producing Enterobacterales (CPE) represent an important threat to global health, resulting in an urgent issue in clinical settings. CPE often exhibit a multidrug-resistant (MDR) phenotype, thus reducing the antimicrobial armamentarium, with few antibiotics retaining residual antimicrobial activity against these pathogens. Carbapenemases are divided into three classes (A, B, and D) according to the Ambler classification system. Among these, KPC (class A), NDM, VIM, IMP (class B), and OXA-48-like (class D) represent the most important carbapenemases in terms of diffusion and clinical impact. CPE diffusion has been observed worldwide, with current endemicity in multiple territories around the world. In this context, the clonal spread and plasmid-mediated transmission of carbapenemases have contributed to the global spread of CPE worldwide and to the diffusion of carbapenemases among different Enterobacterales species. In recent years, novel molecules showing excellent in vitro and in vivo activity have been developed against CPE. However, the recent emergence of novel traits of resistance to these molecules has already been reported in several cases, mitigating the initial promising results. This review aims to provide an updated description of the major classes of carbapenemases, their global distribution, and future perspectives to limit the diffusion of CPEs.

19 March 2019 in Viruses
Verified
Journal Article
Open access
PDF file
Cristiano SalataCristiano Salata
Cristiano Salata
ACArianna Calistri
Arianna Calistri
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
MCMichele Celestino
Michele Celestino
Cristina ParolinCristina Parolin
Cristina Parolin
Giorgio  PalùGiorgio Palù
Giorgio Palù
Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family. The recent large outbreak of EVD in Western Africa (2013–2016) highlighted the worldwide threat represented by the disease and its impact on global public health and the economy. The development of highly needed anti-Ebola virus antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, allowing to screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to study Ebola virus entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus-like particles, tremendously boosted both our knowledge of the viral life cycle and the identification of promising antiviral compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.